UK Markets closed

Zogenix, Inc. (ZGNX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
21.320.00 (0.00%)
At close: 4:00PM EDT

21.32 0.00 (0.00%)
After hours: 4:00PM EDT

Zogenix, Inc.

5959 Horton Street
Suite 500
EmeryVille, CA 94608
United States
510 550 8300

Full-time employees141

Key executives

NameTitlePayExercisedYear born
Dr. Stephen J. FarrCo-Founder, CEO, Pres & Director867.95k5.7M1959
Mr. Michael P. SmithExec. VP, CFO, Treasurer & Sec.573.34k1.7M1968
Dr. Bradley S. GalerExec. VP & Chief Medical Officer582.08kN/A1962
Dr. Gail M. FarfelExec. VP & Chief Devel. Officer568.5kN/A1964
Mr. Ashish M. SagrolikarExec. VP & Chief Commercial Officer541.24kN/A1967
Mr. Jeff D. DurflingerVP of Technical Operations & Product SupplyN/AN/A1961
Ms. Shawnte M. MitchellExec. VP, Gen. Counsel & Sec.N/AN/A1978
Melinda BakerSr. Director of Corp. CommunicationsN/AN/AN/A
Mr. Bret E. MegargelVP of Corp. Devel.N/AN/A1969
Mr. Stephen H. JennerVP of MarketingN/AN/A1968
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Zogenix, Inc., a pharmaceutical company, develops and commercializes transformative therapies to enhance the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS); and which is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It also developing MT1621, an investigational deoxynucleoside substrate enhancement therapy for the treatment of inherited mitochondrial DNA depletion disorder thymidine kinase 2 deficiency (TK2d). The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.

Corporate governance

Zogenix, Inc.’s ISS governance QualityScore as of 31 October 2019 is 7. The pillar scores are Audit: 5; Board: 5; Shareholder rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.